Quest Diagnostics Incorporated (DGX) Receives $104.81 Consensus PT from Brokerages

Shares of Quest Diagnostics Incorporated (NYSE:DGX) have received a consensus recommendation of “Hold” from the twenty-three ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $104.81.

A number of equities analysts have commented on DGX shares. KeyCorp restated a “hold” rating on shares of Quest Diagnostics in a research report on Friday, October 27th. ValuEngine upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. Wells Fargo & Company lowered their price target on shares of Quest Diagnostics from $88.00 to $86.00 and set a “market perform” rating on the stock in a research note on Friday, October 20th. Zacks Investment Research cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Finally, Goldman Sachs Group, Inc. (The) cut shares of Quest Diagnostics from a “conviction-buy” rating to a “buy” rating and lowered their price target for the stock from $121.00 to $113.00 in a research note on Tuesday, October 10th.

In related news, Chairman Stephen H. Rusckowski sold 2,525 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $108.03, for a total value of $272,775.75. Following the transaction, the chairman now owns 168,413 shares in the company, valued at $18,193,656.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Stephen H. Rusckowski sold 53,933 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $108.16, for a total transaction of $5,833,393.28. Following the completion of the transaction, the chief executive officer now owns 220,049 shares in the company, valued at approximately $23,800,499.84. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 160,396 shares of company stock worth $17,343,852. Insiders own 1.75% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. WFG Advisors LP raised its holdings in Quest Diagnostics by 45.3% in the second quarter. WFG Advisors LP now owns 966 shares of the medical research company’s stock valued at $107,000 after buying an additional 301 shares during the period. Sun Life Financial INC grew its position in Quest Diagnostics by 14,142.9% in the second quarter. Sun Life Financial INC now owns 997 shares of the medical research company’s stock valued at $111,000 after acquiring an additional 990 shares in the last quarter. Parallel Advisors LLC grew its position in Quest Diagnostics by 0.9% in the second quarter. Parallel Advisors LLC now owns 1,291 shares of the medical research company’s stock valued at $140,000 after acquiring an additional 12 shares in the last quarter. Acrospire Investment Management LLC grew its position in Quest Diagnostics by 300.0% in the second quarter. Acrospire Investment Management LLC now owns 1,600 shares of the medical research company’s stock valued at $178,000 after acquiring an additional 1,200 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in Quest Diagnostics in the second quarter valued at approximately $180,000. Hedge funds and other institutional investors own 88.52% of the company’s stock.

Quest Diagnostics (DGX) traded up $0.05 during mid-day trading on Thursday, reaching $92.46. 1,328,456 shares of the company traded hands, compared to its average volume of 991,715. Quest Diagnostics has a 1 year low of $86.11 and a 1 year high of $112.96. The stock has a market cap of $12,600.00, a P/E ratio of 16.67, a price-to-earnings-growth ratio of 1.94 and a beta of 0.59. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.37 and a current ratio of 1.47.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, October 19th. The medical research company reported $1.39 EPS for the quarter, topping the Zacks’ consensus estimate of $1.35 by $0.04. The company had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.92 billion. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.53%. Quest Diagnostics’s quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.37 EPS. research analysts anticipate that Quest Diagnostics will post 5.65 EPS for the current year.

WARNING: This article was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://weekherald.com/2017/11/22/quest-diagnostics-incorporated-dgx-receives-104-81-consensus-pt-from-brokerages.html.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply